Carlyle acquires 50 percent stake in Resonetics for USD 2.25 billion: Bloomberg
New Delhi: Carlyle Group Inc. has acquired a 50% stake in medical-device manufacturer Resonetics in a deal that values the target company at about $2.25 billion.
"One of our big theses is providing outsourced services to different health-care end-markets, whether they're hospitals, pharma companies or med-tech companies," Bobby Schmidt, a Carlyle managing director, said in an interview. "We want to invest behind companies that provide services at a higher quality and lower cost than what your customers can do for themselves, and that's exactly what Resonetics does."
Schmidt, whose comments confirmed a November Bloomberg report that the two firms were nearing a deal, is joining Resonetics' board along with fellow Carlyle executive Steve Wise.
"In addition to organic revenue growth, which exceeds 20%, we see an M&A opportunity to grow this company into something much bigger, which is exciting to us," Schmidt said.
Carlyle acquired the stake in Nashua, New Hampshire-based Resonetics from its management as well as GTCR, a Chicago private equity firm under whose ownership Resonetics made eight bolt-on acquisitions. Those include FISO Technologies and Hudson Medical Innovations, Sean Cunningham, a GTCR managing director, said in an emailed statement.
Washington-based Carlyle has a track record of backing medical-products companies such as Medline, Unchained Labs and Ortho Clinical Diagnostics.
Barclays Plc and Debevoise & Plimpton advised Carlyle on the transaction, while Piper Sandler and Kirkland & Ellis advised Resonetics and GTCR.
Read also: Medanta brand owner Global Health to raise funds via IPO
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.